PDF(Pubmed)
Abstract：
IgE-mediated atopic diseases such as allergic rhinitis and rhinoconjunctivitis are common chronic diseases in the western world. Allergen immunotherapy (AIT) plays a fundamental role in the treatment of allergic patients by modulating the underlying immune mechanisms. Though this treatment is integrated in practice-patterns globally, many differences are found in the application of AIT on the national or international level due to heterogeneous methods, and clinical recommendations are given in different parts of the world. This review from authors in Europe and the United States highlights differences and similarities in important aspects of AIT application in the 2 global regions. First, the regulatory situation differs regarding marketing authorization and licensing. Secondly, differences are elaborated in manufacturing practices, marketing distribution and formulations of AIT products. Thirdly, clinical administration patterns in the current guidelines show similarities in indications and contraindications of AIT, but also are divergent in some practical aspects. Informing the readership on similarities, as well as differences of standards in AIT in the United States and Europe, the authors highlight the unmet need of thorough harmonization of standards of AIT, as it is the only disease modifying treatment option available for patients with allergic rhinitis and rhinoconjunctivitis.
摘要：
IgE介导的特应性疾病如过敏性鼻炎和鼻结膜炎是西方世界常见的慢性疾病。变应原免疫疗法(AIT)通过调节潜在的免疫机制在变应性患者的治疗中起着重要作用。尽管这种治疗在全球范围内都融入了实践模式，由于不同的方法，AIT在国家或国际层面的应用存在许多差异，并在世界不同地区给出临床建议。来自欧洲和美国的作者的这篇综述强调了AIT在两个全球地区应用的重要方面的差异和相似之处。首先,在营销授权和许可方面，监管情况有所不同。其次,差异在制造实践中得到了阐述，AIT产品的营销分销和配方。第三，当前指南中的临床管理模式显示AIT的适应症和禁忌症相似，但在一些实际方面也存在分歧。向读者通报相似之处，以及美国和欧洲AIT标准的差异，作者强调了彻底协调AIT标准的未满足需求，因为它是过敏性鼻炎和鼻结膜炎患者唯一的疾病修饰治疗选择。
